Cannabis Law Report
JUNE 30, 2021
In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Building the Data Backend. For more information, visit the company’s website or download their investor presentation. Disclaimer.
Cannabis Law Report
DECEMBER 9, 2021
The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TheAnswerPage
JANUARY 11, 2022
We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety.
Cannabis Law Report
DECEMBER 21, 2021
The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.
Cannabis Law Report
JUNE 10, 2021
Studies of crash or driving data suggest that, although permissive marijuana policies are associated with higher prevalence of tetrahydrocannabinol (THC) presence among drivers [ 1 , 2 ], there is mixed evidence that these policies are associated with motor vehicle crashes [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. never vs. at least once). (2)
Project CBD
FEBRUARY 28, 2023
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.
CannaMD
MARCH 8, 2020
Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. More research is needed.
Expert insights. Personalized for you.
52 
Let's personalize your content